A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with guillain-barré syndrome (GBS): Protocol of Japanese eculizumab trial for GBS (JET-GBS)

JET-GBS Group

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Background: Guillain-Barré syndrome (GBS) is an immune-mediated neuropathy that causes acute flaccid paralysis. Immunoglobulin and plasma exchange are established treatments for GBS; however, a substantial number of patients, particularly those with severe disease, have poor recovery and residual deficits. Recent studies suggest that complement activation plays a pivotal role in GBS-associated axonal degeneration, and eculizumab is a humanized monoclonal antibody that specifically binds to complement component 5 and potently inhibits complement activation. Objective: This clinical trial aims to evaluate the efficacy and safety of eculizumab, a humanized monoclonal antibody directed against complement component 5, for treatment of GBS. Methods: The Japanese Eculizumab Trial for GBS (JET-GBS) is a prospective, multicenter, placebo-controlled, double-blind, randomized phase II study conducted at 13 tertiary neurology centers and is funded by the Japan Agency for Medical Research and Development. A total of 33 GBS patients unable to walk independently within 2 weeks from symptom onset (Hughes functional grade 3-5) were randomized at a 2:1 ratio to receive either intravenous eculizumab (900 mg/day) or placebo once weekly for 4 weeks, followed by 20 weeks of follow-up. The primary endpoint for efficacy is the proportion of patients who regain their ability to walk without aid at 4 weeks after the first dose of the study treatment, while primary safety outcomes are the incidence of adverse events and serious adverse events during the trial. Results: Enrollment for the trial began in August 2015. This trial is still ongoing. All participants have been enrolled, and follow-up will be completed in October 2016. Conclusions: This study is the first to investigate the efficacy and safety of eculizumab for GBS. In case of a positive result, we will plan a phase III trial to investigate this issue in a larger number of patients.

Original languageEnglish
Article numbere210
JournalJMIR Research Protocols
Volume5
Issue number4
DOIs
Publication statusPublished - 2016 Oct

Keywords

  • Antiganglioside antibody
  • Clinical trial
  • Complement activation
  • Eculizumab
  • Guillain-Barré syndrome

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with guillain-barré syndrome (GBS): Protocol of Japanese eculizumab trial for GBS (JET-GBS)'. Together they form a unique fingerprint.

Cite this